An Unexpected Synthesis of a Dihydropyrrolo-[1,2-c]pyrimidinedione Nucleoside Analogue from 5-Fluorouracil†

(Note: The full text of this document is currently only available in the PDF Version )

Ge′raldine Grangier-McMath, David J. Aitken, Dominique Guillaume, Angēle Chiaroni, Claude Riche and Henri-Philippe Husson


Abstract

In the presence of an excess of LDA, the tandem deprotonation–alkylation reaction of 1-cyanomethyl-5-fluorouracil with epibromohydrin gives the novel dihydropyrrolo[1,2-c]pyrimidinedione 4 as a mixture of diastereoisomers.


References

  1. Nucleosides and Nucleotides as Antitumor and Antiviral Agents, ed. C. K. Chu and D. C. Baker, Plenum, New York, 1993 Search PubMed; C. Périgaud, G. Gosselin and J.-L. Imbach, Nucleosides Nucleotides, 1992, 11, 903 Search PubMed; D. M. Huryn and M. Okabe, Chem. Rev., 1992, 92, 1745 CAS.
  2. G. Grangier, D. J. Aitken, D. Guillaume and H.-P. Husson, Tetrahedron Lett., 1994, 35, 4355 CrossRef CAS.
  3. G. Grangier, D. J. Aitken, D. Guillaume, A. Tomas, B. Viossat and H.-P. Husson, J. Heterocycl. Chem., 1994, 31, 1707 CAS.
  4. Uracil and thymine derivatives can also be metallated at C(6) with lithium amide bases; see, for example: H. Tanaka, H. Hayakawa, S. Shibata, K. Haraguchi, T. Miyasaka and K. Hirota, Nucleosides Nucleotides, 1992, 11, 319 Search PubMed; H. Takana, T. Miyasaka, K. Sekiya, H. Takashima, M. Ubasawa, I. Nitta, M. Baba, R. T. Walker and E. De Clercq, Nucleosides Nucleotides, 1992, 11, 447 CAS This phenomenon is not observed with 5a or 5b, presumably because the proton α to the nitrile is more acidic. The order of ease of metallation can therefore be deduced as: 5c C(6) > N CHR CN > 5a,b C(6).
  5. T. Gimisis and C. Chatgilialoglu, J. Org. Chem., 1996, 61, 1908 CrossRef CAS; A. Kittaka, H. Tanaka, Y. Odanaka, K. Ohnuki, K. Yamaguchi and T. Miyasaka, J. Org. Chem., 1994, 59, 3636 CrossRef CAS; Y. Yoshimura, B. A. Otter, T. Ueda and A. Matsuda, Chem. Pharm. Bull., 1992, 40, 1761 CAS.
Click here to see how this site uses Cookies. View our privacy policy here.